Sinopharm Group Co. Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more
Sinopharm Group Co. Ltd (X2S) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.023x
Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has a cash flow conversion efficiency ratio of -0.023x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.63 Billion) by net assets (€113.11 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinopharm Group Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Sinopharm Group Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sinopharm Group Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinopharm Group Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RIT CAP. PARTNERS LS 1
F:1IH
|
N/A |
|
Mediobanca Banca di Credito Finanziario S.p.A.
F:ME90
|
N/A |
|
Box Inc
NYSE:BOX
|
-0.369x |
|
China Communications Services Corporation Limited
PINK:CUCSY
|
0.181x |
|
Industrias CH S. A. B. de C. V
PINK:ICHBF
|
0.014x |
|
Enova International Inc
NYSE:ENVA
|
0.373x |
|
Fuchs Petrolub SE Preference Shares
XETRA:FPE3
|
0.063x |
|
Yes Bank Limited
NSE:YESBANK
|
0.131x |
Annual Cash Flow Conversion Efficiency for Sinopharm Group Co. Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Sinopharm Group Co. Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €126.69 Billion | €11.55 Billion | 0.091x | -36.15% |
| 2023-12-31 | €120.32 Billion | €17.17 Billion | 0.143x | -25.06% |
| 2022-12-31 | €110.07 Billion | €20.96 Billion | 0.190x | +103.91% |
| 2021-12-31 | €99.65 Billion | €9.31 Billion | 0.093x | -24.68% |
| 2020-12-31 | €89.95 Billion | €11.15 Billion | 0.124x | -49.19% |
| 2019-12-31 | €76.94 Billion | €18.78 Billion | 0.244x | +356.05% |
| 2018-12-31 | €68.28 Billion | €3.65 Billion | 0.054x | -14.49% |
| 2017-12-31 | €51.27 Billion | €3.21 Billion | 0.063x | -69.90% |
| 2016-12-31 | €44.53 Billion | €9.26 Billion | 0.208x | -36.64% |
| 2015-12-31 | €40.88 Billion | €13.41 Billion | 0.328x | +114.12% |
| 2014-12-31 | €36.29 Billion | €5.56 Billion | 0.153x | -11.27% |
| 2013-12-31 | €28.61 Billion | €4.94 Billion | 0.173x | -- |